Terms: = Lung cancer AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53 AND Clinical Outcome
107 results:
1. Immune Features of Tumor Microenvironment: A Genetic Spotlight.
Asadi M; Zarredar H; Zafari V; Soleimani Z; Saeedi H; Caner A; Shanehbandi D
Cell Biochem Biophys; 2024 Mar; 82(1):107-118. PubMed ID: 37870699
[TBL] [Abstract] [Full Text] [Related]
2. Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse outcomes in Patients With EGFR-Mutant lung cancer.
Stockhammer P; Grant M; Wurtz A; Foggetti G; Expósito F; Gu J; Zhao H; Choi J; Chung S; Li F; Walther Z; Dietz J; Duffield E; Gettinger S; Politi K; Goldberg SB
J Thorac Oncol; 2024 Feb; 19(2):240-251. PubMed ID: 37806385
[TBL] [Abstract] [Full Text] [Related]
3. NPM3 as a novel oncogenic factor and poor prognostic marker contributes to cell proliferation and migration in lung adenocarcinoma.
Wei S; Xing J; Lu K; Wang K; Yu W
Hereditas; 2023 May; 160(1):27. PubMed ID: 37254219
[TBL] [Abstract] [Full Text] [Related]
4. RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between tp53 Status and clinical outcome.
Nishio M; Paz-Ares L; Reck M; Nakagawa K; Garon EB; Popat S; Ceccarelli M; Graham HT; Visseren-Grul C; Novello S
Clin Lung Cancer; 2023 Jul; 24(5):415-428. PubMed ID: 37076395
[TBL] [Abstract] [Full Text] [Related]
5. The evolution of lung cancer and impact of subclonal selection in TRACERx.
Frankell AM; Dietzen M; Al Bakir M; Lim EL; Karasaki T; Ward S; Veeriah S; Colliver E; Huebner A; Bunkum A; Hill MS; Grigoriadis K; Moore DA; Black JRM; Liu WK; Thol K; Pich O; Watkins TBK; Naceur-Lombardelli C; Cook DE; Salgado R; Wilson GA; Bailey C; Angelova M; Bentham R; Martínez-Ruiz C; Abbosh C; Nicholson AG; Le Quesne J; Biswas D; Rosenthal R; Puttick C; Hessey S; Lee C; Prymas P; Toncheva A; Smith J; Xing W; Nicod J; Price G; Kerr KM; Naidu B; Middleton G; Blyth KG; Fennell DA; Forster MD; Lee SM; Falzon M; Hewish M; Shackcloth MJ; Lim E; Benafif S; Russell P; Boleti E; Krebs MG; Lester JF; Papadatos-Pastos D; Ahmad T; Thakrar RM; Lawrence D; Navani N; Janes SM; Dive C; Blackhall FH; Summers Y; Cave J; Marafioti T; Herrero J; Quezada SA; Peggs KS; Schwarz RF; Van Loo P; Miedema DM; Birkbak NJ; Hiley CT; Hackshaw A; Zaccaria S; ; Jamal-Hanjani M; McGranahan N; Swanton C
Nature; 2023 Apr; 616(7957):525-533. PubMed ID: 37046096
[TBL] [Abstract] [Full Text] [Related]
6. Genomic Characteristics and the Potential clinical Implications in Oligometastatic Non-Small Cell lung cancer.
Liao R; Chen K; Li J; He H; Yi G; Huang M; Chen R; Shen L; Zhang X; Xu Z; Yang Z; Peng Y
Cancer Res Treat; 2023 Jul; 55(3):814-831. PubMed ID: 36634615
[TBL] [Abstract] [Full Text] [Related]
7. The development of a tumor-associated autoantibodies panel to predict clinical outcomes for immune checkpoint inhibitor-based treatment in patients with advanced non-small-cell lung cancer.
Zhao J; Wu Y; Yue Y; Chen M; Xu Y; Liu X; Liu X; Gao X; Wang H; Si X; Zhong W; Zhang X; Zhang L; Wang M
Thorac Cancer; 2023 Feb; 14(5):497-505. PubMed ID: 36594104
[TBL] [Abstract] [Full Text] [Related]
8. Evaluate the Prognosis of
Cao J; J Gu J; Liang Y; Wang B
Technol Cancer Res Treat; 2022; 21():15330338221138213. PubMed ID: 36524293
[No Abstract] [Full Text] [Related]
9. RAS oncogenic activity predicts response to chemotherapy and outcome in lung adenocarcinoma.
East P; Kelly GP; Biswas D; Marani M; Hancock DC; Creasy T; Sachsenmeier K; Swanton C; ; Downward J; de Carné Trécesson S
Nat Commun; 2022 Sep; 13(1):5632. PubMed ID: 36163168
[TBL] [Abstract] [Full Text] [Related]
10. DNA Methylation Profiling Identifies Subgroups of lung Adenocarcinoma with Distinct Immune Cell Composition, DNA Methylation Age, and clinical outcome.
Guidry K; Vasudevaraja V; Labbe K; Mohamed H; Serrano J; Guidry BW; DeLorenzo M; Zhang H; Deng J; Sahu S; Almonte C; Moreira AL; Tsirigos A; Papagiannakopoulos T; Pass H; Snuderl M; Wong KK
Clin Cancer Res; 2022 Sep; 28(17):3824-3835. PubMed ID: 35802677
[TBL] [Abstract] [Full Text] [Related]
11. Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine lung cancer (nNGM).
Janning M; Süptitz J; Albers-Leischner C; Delpy P; Tufman A; Velthaus-Rusik JL; Reck M; Jung A; Kauffmann-Guerrero D; Bonzheim I; Brändlein S; Hummel HD; Wiesweg M; Schildhaus HU; Stratmann JA; Sebastian M; Alt J; Buth J; Esposito I; Berger J; Tögel L; Saalfeld FC; Wermke M; Merkelbach-Bruse S; Hillmer AM; Klauschen F; Bokemeyer C; Buettner R; Wolf J; Loges S;
Ann Oncol; 2022 Jun; 33(6):602-615. PubMed ID: 35263633
[TBL] [Abstract] [Full Text] [Related]
12. Identification and functional analysis of lncRNAs and mRNAs between tumorigenesis and metastasis in CRC.
Liu H; Tian Y; Li J; Zhang G; Liu Q; Yang M; Yue L; Cao Q; Zhang G; Cheng Y; Kong N; Fang L; Li S; Sun Q
Aging (Albany NY); 2021 Dec; 13(24):25859-25885. PubMed ID: 34954693
[TBL] [Abstract] [Full Text] [Related]
13. EphB4 as a Novel Target for the EGFR-Independent Suppressive Effects of Osimertinib on Cell Cycle Progression in Non-Small Cell lung cancer.
Nanamiya R; Saito-Koyama R; Miki Y; Inoue C; Asavasupreechar T; Abe J; Sato I; Sasano H
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445227
[TBL] [Abstract] [Full Text] [Related]
14. The Effect of GLUT1 on the Survival Rate and Immune Cell Infiltration of lung Adenocarcinoma and Squamous Cell Carcinoma: A Meta and Bioinformatics Analysis.
Zhang G; Dong R; Kong D; Liu B; Zha Y; Luo M
Anticancer Agents Med Chem; 2022; 22(2):223-238. PubMed ID: 34238200
[TBL] [Abstract] [Full Text] [Related]
15. Immune landscape and a promising immune prognostic model associated with tp53 in early-stage lung adenocarcinoma.
Wu C; Rao X; Lin W
Cancer Med; 2021 Feb; 10(3):806-823. PubMed ID: 33314730
[TBL] [Abstract] [Full Text] [Related]
16. RNA-Seq Analysis of Cisplatin and the Monofunctional Platinum(II) Complex, Phenanthriplatin, in A549 Non-Small Cell lung cancer and IMR90 lung Fibroblast Cell Lines.
Monroe JD; Moolani SA; Irihamye EN; Speed JS; Gibert Y; Smith ME
Cells; 2020 Dec; 9(12):. PubMed ID: 33302475
[TBL] [Abstract] [Full Text] [Related]
17. SMARCA4 mutations in KRAS-mutant lung adenocarcinoma: a multi-cohort analysis.
Liu L; Ahmed T; Petty WJ; Grant S; Ruiz J; Lycan TW; Topaloglu U; Chou PC; Miller LD; Hawkins GA; Alexander-Miller MA; O'Neill SS; Powell BL; D'Agostino RB; Munden RF; Pasche B; Zhang W
Mol Oncol; 2021 Feb; 15(2):462-472. PubMed ID: 33107184
[TBL] [Abstract] [Full Text] [Related]
18. Steroid receptor-associated and regulated protein is a biomarker in predicting the clinical outcome and treatment response in malignancies.
Naderi A
Cancer Rep (Hoboken); 2020 Oct; 3(5):e1267. PubMed ID: 32706923
[TBL] [Abstract] [Full Text] [Related]
19. Integrative Proteomic Characterization of Human lung Adenocarcinoma.
Xu JY; Zhang C; Wang X; Zhai L; Ma Y; Mao Y; Qian K; Sun C; Liu Z; Jiang S; Wang M; Feng L; Zhao L; Liu P; Wang B; Zhao X; Xie H; Yang X; Zhao L; Chang Y; Jia J; Wang X; Zhang Y; Wang Y; Yang Y; Wu Z; Yang L; Liu B; Zhao T; Ren S; Sun A; Zhao Y; Ying W; Wang F; Wang G; Zhang Y; Cheng S; Qin J; Qian X; Wang Y; Li J; He F; Xiao T; Tan M
Cell; 2020 Jul; 182(1):245-261.e17. PubMed ID: 32649877
[TBL] [Abstract] [Full Text] [Related]
20. Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.
Mu Y; Hao X; Xing P; Hu X; Wang Y; Li T; Zhang J; Xu Z; Li J
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2427-2433. PubMed ID: 32385709
[TBL] [Abstract] [Full Text] [Related]
[Next]
